Terumo (OTCMKTS:TRUMY) Stock Rating Raised to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Terumo (OTCMKTS:TRUMY) from a hold rating to a strong-buy rating in a report published on Tuesday,Zacks reports.

Separately, Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, Terumo currently has a consensus rating of “Strong Buy”.

Terumo Price Performance

TRUMY stock opened at $14.15 on Tuesday. Terumo has a 52 week low of $12.08 and a 52 week high of $17.81. The firm has a market capitalization of $20.87 billion, a P/E ratio of 19.93 and a beta of 0.77. The company has a fifty day simple moving average of $15.11 and a two-hundred day simple moving average of $14.22. The company has a quick ratio of 1.37, a current ratio of 2.19 and a debt-to-equity ratio of 0.13.

Terumo (OTCMKTS:TRUMY) last announced its earnings results on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.13. Terumo had a net margin of 13.83% and a return on equity of 10.44%. The firm had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Analysts anticipate that Terumo will post 0.86 earnings per share for the current fiscal year.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.

Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.